A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe
2020 · Journal of Experimental & Clinical Cancer Research · 14 citations
https://doi.org/10.1186/s13046-020-01597-9